Novo Nordisk · 21 hours ago
Internship - Patient Engagement Solutions Analysis
Plainsboro, NJ
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company dedicated to improving health outcomes. The Patient Engagement Solutions Analysis intern will work on innovative consumer-focused solutions, assisting with technical requirements, creating test cases, and ensuring content accuracy in the application.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Help manage technical requirements in Azure DevOps
Assist with creating Test cases and Test scripts
Assist with tagging and uploading content in the content management platform
Testing to ensure content in the application correctly reflects approved versions
Assist in any documentation related to above listed responsibilities
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than May 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate degree in Data Science, Computer Science, AI or a related discipline preferred
Class year of a junior or senior preferred
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase